ArticleActa pharmacologica Sinica2025

Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.

Chen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.